The results of a large international case-control study of acute and nonlymphocytic leukemia following irradiation for cancer of the cervix was reported in 1987 (7,2). These reports followed publication of a cohort study of part of the total material included in the case-control study (3). The casecontrol results (7,2) contained a puzzling feature: Simple tabulation of the relative risks by average dose level suggested a curvilinear dose response, indicative of a cell-killing effect (Table 1 , a), but formal statistical analysis provided no significant departures from the null model. The case-control study thus appears to contain little information to discriminate among different dose-response models, contrary to the superficial impression given by the odds ratios. The problem is well known in epidemiology and stems from the uncertainty regarding the baseline risk (4). The data on which Table 1 , a, are based contain only eight unexposed cases; therefore, confidence intervals for the excess risk relative to the nonexposed as baseline are wide for each dose level. These wide confidence intervals are clearly consistent with a wide range of doseresponse curves (including the null). The earlier cohort study, however, showed a highly significant increase in risk for acute and nonlymphocytic leukemia, especially in years 1-9 after irradiation [40 observed, 22.8 expected,
This high level of significance suggests that, if one took the rates in the general population as baseline, the case-control results might better discriminate among different doseresponse alternatives. Analytically, this procedure consists of combining the results from the case-control and the cohort components of the overall study by maximizing the joint likelihood for the two comparisons (5). The justification for treating the general population as a valid baseline for the case-control study is that there is little evidence-either epidemiological or biological-of a relationship between cancer of the cervix and leukemia and that among the nonirradiated patients in the cohort study, the observed number and the expected number of cases were almost the same (six observed versus 5.4 expected).
The Data Committee of the International Cervix Cancer Study released to us the basic data of the leukemia casecontrol study. We have combined these data with the published results of the cohort study [Tables B19 and A2 of ref. (5) Table 1 , b, indicates a substantial narrowing of the confidence intervals at each dose level. The generally lower levels of relative risk in Table 1 , b, reflect the reduction in the uncertainty over the baseline compared with that in Table 1 , a. The conclusions to be drawn from the likelihood ratio tests in Table 1 , b, are that there is a highly significant linear dose-response effect and that appreciable improvement in the fit (P = .03) is obtained by including a cell-killing effect. Further analyses incorporating the effects of age and latency suggest that the significance of the cell-killing effect is considerably reduced by adjusting for these two variables (5). In Table 1 , a, the overall model of a linear dose effect with cell killing does not approach significance, which makes the marginal significance of the cellkilling effect difficult to interpret. The combined analysis of the cohort and the case-control data thus provides clearer comparison of dose-response models than is given by either the cohort or the case-control data alone. Similar analyses of the data for other sites where an excess risk is suggested are planned. The natural history of gastric carcinoma is difficult to study because therapy is usually offered and accepted, except in advanced cases. We have recently had the opportunity to study the natural history of gastric cancer in a 43-year-old woman. This patient presented with right-sided malignant pleural effusion due to metastatic adenocarcinoma from a malignant ulcer on the lesser curvature of the stomach. Hospital records revealed that she had been seen here for hematemesis 84 months previously. Endoscopy at that time had revealed a 2-cm ulcer on the lesser curve. On biopsy, this ulcer had been documented to be a poorly differentiated adenocarcinoma. The patient refused surgery at this center but was operated on in another hospital. The surgeon's notes indicate that, since he did not find any evidence of tumor at laparotomy and gastrostomy, gastric resection was not done. (This fact was confirmed at endoscopy.) The woman did not receive any cytotoxic agents. She remained completely asymptomatic until her presentation to us exactly 7 years after the initial diagnosis was made. She has now been treated with pleurodesis (using tetracycline), and chemotherapy has been started. This patient's gastric malignancy appears to be very indolent, and its slow growth resembles the growth of the cases reported by Bodner et al. (7). Those investigators followed three patients, who could not be operated on for early gastric cancer, to their deaths due to unrelated causes at 36, 30, and 11 months after diagnosis. At postmortem examination, there was no evidence of the spread of disease to regional lymph nodes or to the liver.
Our experience with the present case raises a pertinent question: Is the excellent 90% 5-year survival (2) quoted in the literature for early gastric cancer due to the early and aggressive gastric resection or to the inherent indolent nature of some gastric malignancies?
ALKA GANESH, M.D. (7) recently reported on the treatment of several patients with ovarian and other types of cancer with L-buthionine sulfoximine (BSO), a selective inhibitor of -y-glutamylcysteine synthetase {2-4). This enzyme catalyzes the first and ratelimiting step of glutathione synthesis, and its inhibition decreases cellular glutathione. This treatment of drugand radiation-resistant tumors is based on research which showed that these tumors have increased levels of glutathione, which can protect the tumor cells against the effects of chemotherapeutic agents and radiation (5-10). Some tumors may have increased capacity for glutathione synthesis (10). Such resistance may be reversed by treatment with BSO [an analogue of methionine sulfoximine (II)] in experimental model systems . The studies of O'Dwyer et al. (7) are encouraging in that they show that, when these patients were treated with BSO, their peripheral mononuclear cell levels of glutathione decreased to less than 20% of the control levels in about one half of the patients treated. The success of this therapeutic approach will ultimately depend on whether tumor levels of glutathione can be decreased without producing unacceptable toxic effects in the normal cells.
Department of Medicine III
I wish to call attention to a new aspect of glutathione deficiency, which was initially illuminated through studies on newborn rats. In these studies (72), administration of relatively high doses of BSO to newborn rats led to marked decreases in tissue levels of glutathione and of ascorbate, increased levels of dehydroascorbate, and toxic effects. Interestingly, administration of ascorbate not only restored tissue ascorbate to normal levels, but also protected against toxic effects and spared glutathione; thus, mitochondrial levels of glutathione in BSO-treated newborn rats were increased twofold to sixfold by giving ascorbate (12, 13) . Similar findings were made in analogous studies on guinea pigs (14). Newborn rats (like guinea pigs and humans) do not appear to synthesize ascorbate.
Guinea pigs, like newborn rats, can be rescued from the effects of severe glutathione deficiency by treatment with ascorbate. Adult mice also show decreased tissue levels of ascorbate when glutathione deficiency is produced by giving BSO. These and related findings (12) (13) (14) (15) , including the observation that administration of glutathione monoethyl ester to ascorbatedeficient guinea pigs delays the onset of scurvy (76), indicate that ascorbate and glutathione have important cellular functions in common. Thus, ascorbate can perform some functions of glutathione, and glutathione is normally required for in vivo functioning of ascorbate.
The observed physiological connections between ascorbate and glutathione and the associated metabolic redundancy of these antioxidants indicate that it is probably important to examine the ascorbic acid status of
